A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

A Randomized MRI-Based Study Reveals VasQ External Support Promotes More Stable Hemodynamics than Standard AVFs

Dr. Andrea Remuzzi and his research team at The University of Bergamo have recently published a randomized-controlled MRI-based computational fluid dynamic study in the Journal of Vascular Access that revealed the impact of VasQ™ External Support on fistula morphology and flow.

VasQ External Support, a Laminate Medical Technologies device is implanted around the connection between the vein and artery during the creation of an arteriovenous fistula (AVF) for hemodialysis patients with the intent to provide structural reinforcement and promote a more stable flow profile.

The MRI study confirmed the device retained a more optimal geometric configuration over the 1-year study period, which promoted a more stable hemodynamic profile. Control patients on the other hand, experienced significant morphological changes, such as atrial “tenting” and angular degradation, that resulted in either an aneurysmal or stenotic AVF with a less stable flow profile.

Dr. Remuzzi stated that, “Morphology is an important surgical consideration to create favorable hemodynamics for fistula maturation and long-term success. Our initial results demonstrated that implanting the VasQ External Support during creation surgery can retain the desired fistula morphology over the long-term that otherwise maybe negatively altered as the tissue undergoes remodeling.”

Several clinical studies conducted in Europe and the U.S. have described an increase in the rate of fistula maturation to become usable for hemodialysis.1-4 However, Dr. Remuzzi’s study was the first of its kind to demonstrate the potential structural and hemodynamic effect of VasQ that may explain the consistent beneficial clinical outcomes that have been reported to date.

Tammy Gilon, Co-founder and CEO of Laminate, commented, “Seeing the vision my co-founder, Eyal Orion, and I had for the device when we first designed it ten years ago come to fruition in patients is a major milestone for Laminate. We appreciate the scientific rigor and expertise Dr. Remuzzi and his team provided in elucidating how VasQ works to create more usable fistulas.”

To date, Laminate has CE mark and has submitted for market clearance in the U.S. to the FDA.

The full publication is now available for open access at Journal of Vascular Access.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy